Septerna to Participate in Upcoming Investor Conferences
Get Alerts SEPN Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:
Wells Fargo 21st Annual Healthcare Conference
Fireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET
Cantor Global Healthcare Conference 2026
Fireside chat on Thursday, September 10, 2026, at 11:30 a.m. ET
A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
[email protected]
Media Contact:
Carly Scaduto, THRUST
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QCI Introduces Trip-Based Analysis for Host and Marketing Teams
- Patton and alfanar Partner™ to Accelerate Secure Digital Transformation of Saudi Power Infrastructure
- Inventus Announces Grant of Stock Options
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share